BriaCell Therapeutics Corp. Warrant (BCTXZ)
CA — Healthcare Sector
Automate Your Wheel Strategy on BCTXZ
With Tiblio's Option Bot, you can configure your own wheel strategy including BCTXZ - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
About BriaCell Therapeutics Corp. Warrant (BCTXZ)
- IPO Date 2025-04-25
- Website https://www.briacell.com
- Industry Biotechnology
- CEO William V. Williams
- Employees 16
BriaCell Therapeutics Corp., an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell cancer vaccine that is in Phase I/IIa clinical trials in combination with the immunotherapy development candidates retifanlimab. The company is also developing Bria-OTS, an off-the-shelf personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test that determines the patients' HLA types. It has a non-exclusive clinical trial collaboration with Incyte Corporation to evaluate the effects of combinations of novel clinical candidates; and a cooperative research and development agreement with the National Cancer Institute to conduct preclinical studies to develop and test Bria-OTS cellular immunotherapy as a treatment for cancer. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.